-
Signature
-
/s/ Jonathan Young, Attorney-in-Fact
-
Stock symbol
-
AKRO
-
Transactions as of
-
Jun 1, 2023
-
Transactions value $
-
-$1,090,971
-
Form type
-
4
-
Date filed
-
6/5/2023, 06:23 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
AKRO |
Common Stock |
Options Exercise |
$13.1K |
+21.3K |
+5.21% |
$0.62* |
431K |
Jun 1, 2023 |
Direct |
F1 |
transaction |
AKRO |
Common Stock |
Options Exercise |
$23.3K |
+3.67K |
+0.85% |
$6.36* |
434K |
Jun 1, 2023 |
Direct |
F1 |
transaction |
AKRO |
Common Stock |
Sale |
-$173K |
-3.91K |
-0.9% |
$44.18 |
430K |
Jun 1, 2023 |
Direct |
F1, F2 |
transaction |
AKRO |
Common Stock |
Sale |
-$936K |
-20.7K |
-4.81% |
$45.26 |
410K |
Jun 1, 2023 |
Direct |
F1, F3 |
transaction |
AKRO |
Common Stock |
Sale |
-$18.4K |
-400 |
-0.1% |
$45.90 |
409K |
Jun 1, 2023 |
Direct |
F1, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
AKRO |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-21.3K |
-24.84% |
$0.00 |
64.5K |
Jun 1, 2023 |
Common Stock |
21.3K |
$0.62 |
Direct |
F1, F5 |
transaction |
AKRO |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3.67K |
-2.55% |
$0.00 |
140K |
Jun 1, 2023 |
Common Stock |
3.67K |
$6.36 |
Direct |
F1, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: